🇺🇸 Ceftriaxone plus vancomycin in United States

9 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Brain Oedema — 1 report (11.11%)
  2. Coma — 1 report (11.11%)
  3. Drug-Induced Liver Injury — 1 report (11.11%)
  4. Headache — 1 report (11.11%)
  5. Hepatic Failure — 1 report (11.11%)
  6. Renal Impairment — 1 report (11.11%)
  7. Thrombotic Microangiopathy — 1 report (11.11%)
  8. Toxicity To Various Agents — 1 report (11.11%)
  9. Vomiting — 1 report (11.11%)

Source database →

Ceftriaxone plus vancomycin in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Ceftriaxone plus vancomycin approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Ceftriaxone plus vancomycin in United States?

Forest Laboratories is the originator. The local marketing authorisation holder may differ — check the official source linked above.